Variant
TP53 Deleterious Mutation
CI-VAR-00000628Explore in graph →CIViC 221
Curated evidence
Evidence by cancer (7 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22090360
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Head and Neck Squamous Cell Carcinoma1 | ||||||||
| TP53 Deleterious Mutation | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID517In a study of 74 patients with head and neck squamous cell carcinoma, those with disruptive mutations in TP53 had shorter overall survival and a higher rate of locoregional recurrence than those witho… (full text at CIViC) PMID 22090360 · Skinner et al., 2012 · Open in CIViC | civic |
| Leukemia1 | ||||||||
| TP53 Deleterious Mutation | RG7112 | Predictive | B | Supports Resistance | 3 | accepted | EID2966Phase I Trial of MDM2 inhibitor RG7112 in 116 patients with AML, ALL, CML, CLL, sCLL demonstrated sustained clinical improvement and induction of TP53 target genes in subset of patients with wild type… (full text at CIViC) PMID 26459177 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available